FI954805A - Menetelmiä insuliininkaltaisen kasvutekijän sitojaproteiinien käyttämiseksi - Google Patents

Menetelmiä insuliininkaltaisen kasvutekijän sitojaproteiinien käyttämiseksi Download PDF

Info

Publication number
FI954805A
FI954805A FI954805A FI954805A FI954805A FI 954805 A FI954805 A FI 954805A FI 954805 A FI954805 A FI 954805A FI 954805 A FI954805 A FI 954805A FI 954805 A FI954805 A FI 954805A
Authority
FI
Finland
Prior art keywords
insulin
methods
growth factor
binding proteins
factor binding
Prior art date
Application number
FI954805A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI954805A0 (fi
Inventor
George N Cox
Deborah A Russell
Original Assignee
Amgen Boulder Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Boulder Inc filed Critical Amgen Boulder Inc
Publication of FI954805A0 publication Critical patent/FI954805A0/fi
Publication of FI954805A publication Critical patent/FI954805A/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4743—Insulin-like growth factor binding protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
FI954805A 1993-04-07 1995-10-09 Menetelmiä insuliininkaltaisen kasvutekijän sitojaproteiinien käyttämiseksi FI954805A (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4526593A 1993-04-07 1993-04-07
PCT/US1994/003755 WO1994022466A1 (en) 1993-04-07 1994-04-06 Methods of using insulin-like growth factor binding proteins

Publications (2)

Publication Number Publication Date
FI954805A0 FI954805A0 (fi) 1995-10-09
FI954805A true FI954805A (fi) 1995-11-15

Family

ID=21936902

Family Applications (1)

Application Number Title Priority Date Filing Date
FI954805A FI954805A (fi) 1993-04-07 1995-10-09 Menetelmiä insuliininkaltaisen kasvutekijän sitojaproteiinien käyttämiseksi

Country Status (7)

Country Link
EP (1) EP0708655A1 (zh)
JP (1) JPH08508296A (zh)
CN (1) CN1134111A (zh)
AU (1) AU6626794A (zh)
CA (1) CA2160154A1 (zh)
FI (1) FI954805A (zh)
WO (1) WO1994022466A1 (zh)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10500693A (ja) * 1994-05-24 1998-01-20 アムジエン・ブルダー・インコーポレーテツド 改変型インスリン様増殖因子
US7153943B2 (en) 1997-07-14 2006-12-26 Bolder Biotechnology, Inc. Derivatives of growth hormone and related proteins, and methods of use thereof
US20080076706A1 (en) 1997-07-14 2008-03-27 Bolder Biotechnology, Inc. Derivatives of Growth Hormone and Related Proteins, and Methods of Use Thereof
US6753165B1 (en) 1999-01-14 2004-06-22 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
WO1999003887A1 (en) 1997-07-14 1999-01-28 Bolder Biotechnology, Inc. Derivatives of growth hormone and related proteins
US7495087B2 (en) 1997-07-14 2009-02-24 Bolder Biotechnology, Inc. Cysteine muteins in the C-D loop of human interleukin-11
AU6515499A (en) * 1998-10-16 2000-05-08 Musc Foundation For Research Development Fragments of insulin-like growth factor binding protein and insulin-like growth factor, and uses thereof
ATE526401T1 (de) 1999-01-14 2011-10-15 Bolder Biotechnology Inc Verfahren zur herstellung von proteinen mit freien cysteinresten
US8288126B2 (en) 1999-01-14 2012-10-16 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
AU3579200A (en) * 1999-02-26 2000-09-14 Saltech I Goteborg Ab Method and composition for the regulation of hepatic and extrahepatic productionof insulin-like growth factor-1
AUPR030900A0 (en) * 2000-09-22 2000-10-12 Queensland University Of Technology Growth factor complex
US20040186051A1 (en) 2001-10-02 2004-09-23 Kelley Robert F Apo-2 ligand variants and uses thereof
EP2500032A1 (en) 2002-06-24 2012-09-19 Genentech, Inc. APO-2 ligand/trail variants and uses thereof
AU2004278311A1 (en) 2003-10-03 2005-04-14 Genentech, Inc. IGF binding proteins
WO2007041614A2 (en) 2005-10-03 2007-04-12 Bolder Biotechnology, Inc. Long acting vegf inhibitors and methods of use
WO2008019491A1 (en) * 2006-08-16 2008-02-21 National Research Council Of Canada Inhibition of angiogenesis, tumorigenesis and cathepsin activity using insulin-like growth factor binding protein
KR20160042438A (ko) 2013-08-12 2016-04-19 제넨테크, 인크. 보체-연관 상태의 치료를 위한 조성물 및 방법
CN106536561A (zh) 2014-05-01 2017-03-22 豪夫迈·罗氏有限公司 抗‑因子d抗体变体及其用途
WO2017075252A1 (en) 2015-10-30 2017-05-04 Genentech, Inc. Anti-factor d antibody variant conjugates and uses thereof
JP2018534930A (ja) 2015-10-30 2018-11-29 ジェネンテック， インコーポレイテッド 抗ｄ因子抗体及びコンジュゲート
US11179451B2 (en) * 2016-11-01 2021-11-23 Virginia Commonwealth University Methods of treating an IGFBP-3R expressing cancer using anti-IGFBP-3R antibodies
CR20220489A (es) 2020-03-24 2022-10-31 Genentech Inc Agentes de fijación a tie2 y métodos de uso.
CN116144667B (zh) * 2022-12-29 2024-03-12 海南大学 卵形鲳鲹胰岛素样生长因子结合蛋白1基因、蛋白及应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK131988A (da) * 1988-03-11 1989-09-12 Erasmus University Igf-bindingsprotein, dna-struktur, der koder for igf-bindingsproteinet og vektor indeholdende denne dna-struktur
EP0418230B1 (en) * 1988-04-12 1995-12-27 Amgen Boulder Inc. Method for potentiating and inhibiting insulin-like growth factor activity
GB8826451D0 (en) * 1988-11-11 1988-12-14 Sandoz Ltd Improvements in/relating to organic compounds
DK0575545T3 (da) * 1991-03-15 2003-09-15 Amgen Inc Pegylering af polypeptider

Also Published As

Publication number Publication date
JPH08508296A (ja) 1996-09-03
AU6626794A (en) 1994-10-24
CA2160154A1 (en) 1994-10-13
EP0708655A1 (en) 1996-05-01
FI954805A0 (fi) 1995-10-09
WO1994022466A1 (en) 1994-10-13
CN1134111A (zh) 1996-10-23

Similar Documents

Publication Publication Date Title
FI954805A0 (fi) Menetelmiä insuliininkaltaisen kasvutekijän sitojaproteiinien käyttämiseksi
GB9225453D0 (en) Binding proteins
FI973543A (fi) Menetelmä heteromultimeeristen polypeptidien valmistamiseksi
DE69410636D1 (de) Bindungsbestimmung
IL107742A0 (en) Chemically-modified binding proteins
FI961071A0 (fi) Menetelmä zeoliitin valmistamiseksi
AU5283793A (en) Recombinant specific binding protein
AU2866695A (en) E6 binding proteins
DE69413830T2 (de) Verfahren zur sulfonierung von olefinen mit innenständiger doppelbindung
DK132892D0 (da) Proteiner
IL110938A0 (en) Plant proteins
EP0796321A4 (en) PROTEINS BINDING TO PROTEIN E2
GB9314802D0 (en) Modified proteins
EP0546081A4 (en) New insulin-like growth factor binding protein (igfbp-4)
AU3640397A (en) Ob protein binding protein
HU9400526D0 (en) Anti-microbial proteins
IL115317A0 (en) Proteins
GB9413316D0 (en) Novel proteins
DE69223434T2 (de) Calmodulin bindendes Protein
IT1248875B (it) Metodo per la legatura di libri
SE9202720D0 (sv) Fibrinogen binding protein
GB9313070D0 (en) Binding protein
AU4795493A (en) Salicylic acid binding protein
EP0751784A4 (en) THYROXIN BINDING PROTEINS
KR940025131U (ko) 결속용 연결구

Legal Events

Date Code Title Description
FD Application lapsed